Physician profile
Hal Applebaum
NPI 1639186042
$6,862.40
in general payments reported to CMS, 2019-2025
30 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,479 · 2020: $1,376 · 2021: $1,582 · 2022: $1,194 · 2023: $230.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $230.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $230.34 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $1,051.50 | 2019-2020 | |
| Amgen INC. | $917.09 | 2019-2023 | Repatha |
| Amarin Pharma, INC. | $802.53 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $783.72 | 2019-2023 | Jardiance |
| Janssen Pharmaceuticals, INC | $625.54 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $395.33 | 2019-2023 | |
| Pfizer INC. | $309.60 | 2019-2022 | |
| Regeneron Healthcare Solutions, INC. | $308.71 | 2019-2022 | |
| Abbott Laboratories | $213.78 | 2019-2021 | |
| Sanofi-Aventis U.S. LLC | $210.06 | 2019-2021 | |
| E.R. Squibb & Sons, L.L.C. | $197.63 | 2019-2022 | |
| Bardy Diagnostics, INC. | $173.00 | 2020-2021 | |
| Astrazeneca Pharmaceuticals Lp | $148.64 | 2019-2022 | |
| Esperion Therapeutics, INC. | $117.75 | 2020-2023 | Nexletol |
| Edwards Lifesciences Corporation | $89.22 | 2019-2020 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $62.04 | 2019-2022 | |
| Lundbeck LLC | $57.90 | 2019 | |
| Medtronic Vascular, INC. | $56.53 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $56.18 | 2021-2022 | |
| Medtronic, INC. | $41.66 | 2021-2022 | |
| Preventice Services, LLC | $41.18 | 2020-2021 | |
| Astellas Pharma US INC | $38.22 | 2019-2020 | |
| Abiomed | $33.14 | 2022 | |
| Kowa Pharmaceuticals America, INC. | $27.26 | 2019-2021 | |
| Chiesi USA, INC. | $24.10 | 2019-2020 | |
| Actelion Pharmaceuticals US, INC. | $20.21 | 2022 | |
| Novo Nordisk INC | $19.25 | 2021 | |
| Philips North America LLC | $17.16 | 2022 | |
| Portola Pharmaceuticals, LLC | $12.37 | 2019 | |
| Kiniksa Pharmaceuticals, Ltd. | $11.10 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Hal Applebaum listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.